SciELO - Scientific Electronic Library Online

 
vol.17 issue1Perfil biosociodemográfico del cuidador principal informal del adulto mayor en una región de EcuadorMucormicosis pulmonar no asociada a inmunodepresión en paciente pediátrico. Caso clínico author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Eugenio Espejo

On-line version ISSN 2661-6742Print version ISSN 1390-7581

Abstract

VERDEZOTO UNDA, Stella Damaris; ESTRELLA CAHUENAS, Bertha Magdalena  and  ROBLES AGUIRRE, Renato Samuel. Sobrevida en población pediátrica con leucemia linfoblástica aguda tratada con protocolo ALLIC-BFM de quimioterapia. Revisión sistemática. Rev Eug Esp [online]. 2023, vol.17, n.1, pp.78-97. ISSN 2661-6742.

Acute lymphoblastic leukemia is the most common childhood neoplasia. Current treatments allow more than 80% disease-free survival for five years. In 2000, a chemotherapy protocol called Berlin-Frankfurt-Münster intercontinental lymphoblastic leukemia (ALLIC BFM) was tested. The investigative process was carried out using the PRISMA methodology. This study aimed to systematize the information about the survival of pediatric patients with acute lymphoblastic leukemia treated with the ALLIC BFM chemotherapy protocol in its 2002 or 2009 versions. 52% to 91.7% of patients showed an overall survival in patients where the 2002 protocol was used, and disease-free was from 45% to 83.3%; while, with the use of the 2009 protocol, an overall survival of 71.1% to 90% was reported, and disease-free survival was 69.4% to 90.3%. The main factors affecting survival were treatment-related complications, high-risk patients, and insufficient medication.

Keywords : Leukemia Lymphoid; Survival Analysis;; Drug Therapy; Child.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )